Literature DB >> 32355672

Appraisal of the current guidelines for management of cholangiocarcinoma-using the Appraisal of Guidelines Research and Evaluation II (AGREE II) Instrument.

Paschalis Gavriilidis1, Alan Askari2, Keith J Roberts1, Robert P Sutcliffe1.   

Abstract

Cholangiocarcinoma (CC) is the second most common primary liver tumour. High-quality guidelines are essential for effective patient stratification and individualised treatment. This study aimed to appraise the methodological quality of existing guidelines for the resection of CC using the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument. A systematic search of the literature in Cochrane, PubMed, Google Scholar, and Embase was performed. Assessment of the clinical practice guidelines (CPGs) and consensuses was performed using the AGREE II instrument by four clinicians experienced in surgical practice and the AGREE II appraisal method. Literature searches identified 13 guidelines of highly variable quality according to the AGREE II criteria. The guidelines scored well in certain domains such as scope & purpose (median score across all guidelines; 65%), clarity of presentation (76%), and editorial independence (56%). However, they scored poorly for applicability (13%), rigour of development (30%), and stakeholder involvement (39%). None of the 13 guidelines was recommended universally for use without modification. Overall, the methodological quality of guidelines on the surgical management of CC is poor. Future updates should address and modify shortcomings detected by the AGREE II instrument, thereby facilitating better patient stratification and individualised treatment strategies. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Appraisal of Guidelines for Research and Evaluation instrument (AGREE II instrument); Cholangiocarcinoma (CC); clinical practice guidelines (CPGs)

Year:  2020        PMID: 32355672      PMCID: PMC7188526          DOI: 10.21037/hbsn.2019.09.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  28 in total

1.  AGREE II: advancing guideline development, reporting, and evaluation in health care.

Authors:  Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger
Journal:  Prev Med       Date:  2010-08-20       Impact factor: 4.018

Review 2.  The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies.

Authors:  Pablo Alonso-Coello; Affan Irfan; Ivan Solà; Ignasi Gich; Mario Delgado-Noguera; David Rigau; Sera Tort; Xavier Bonfill; Jako Burgers; Holger Schunemann
Journal:  Qual Saf Health Care       Date:  2010-12

3.  Evaluation of the current guidelines for resection of hepatocellular carcinoma using the Appraisal of Guidelines for Research and Evaluation II instrument.

Authors:  Pascal Gavriilidis; Keith J Roberts; Alan Askari; Robert P Sutcliffe; Teh-la Huo; Po-Hong Liu; Ernest Hidalgo; Philippe Compagnon; Chetana Lim; Daniel Azoulay
Journal:  J Hepatol       Date:  2017-07-08       Impact factor: 25.083

4.  GUIDELINE FOR THE MANAGEMENT OF BILE DUCT CANCERS BY THE BRAZILIAN GASTROINTESTINAL TUMOR GROUP.

Authors:  Rachel Riechelmann; Anelisa K Coutinho; Rui F Weschenfelder; Gustavo Andrade DE Paulo; Gustavo Dos Santos Fernandes; Markus Gifoni; Maria de Lourdes Oliveira; Rene Gansl; Roberto Gil; Gustavo Luersen; Lucio Lucas; Marcio Reisner; Fernando Meton Vieira; Marcel Autran Machado; Andre Murad; Alessandro Osvaldt; Miguel Brandão; Elisangela Carvalho; Tulio Souza; Tulio Pfiffer; Gabriel Prolla
Journal:  Arq Gastroenterol       Date:  2016 Jan-Mar

5.  Proximal bile duct stricture disguised as malignant neoplasm.

Authors:  A Nakayama; H Imamura; R Shimada; S Miyagawa; M Makuuchi; S Kawasaki
Journal:  Surgery       Date:  1999-05       Impact factor: 3.982

6.  Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO).

Authors:  Domenico Alvaro; Renato Cannizzaro; Roberto Labianca; Francesca Valvo; Fabio Farinati
Journal:  Dig Liver Dis       Date:  2010-08-11       Impact factor: 4.088

Review 7.  Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma.

Authors:  Rungsun Rerknimitr; Phonthep Angsuwatcharakon; Thawee Ratanachu-ek; Christopher J L Khor; Ryan Ponnudurai; Jong Ho Moon; Dong Wan Seo; Linda Pantongrag-Brown; Apichat Sangchan; Pises Pisespongsa; Thawatchai Akaraviputh; Nageshwar D Reddy; Amit Maydeo; Takao Itoi; Nonthalee Pausawasdi; Sundeep Punamiya; Siriboon Attasaranya; Benedict Devereaux; Mohan Ramchandani; Khean-Lee Goh
Journal:  J Gastroenterol Hepatol       Date:  2013-04       Impact factor: 4.029

Review 8.  Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review.

Authors:  Patryk Kambakamba; Michael Linecker; Ksenija Slankamenac; Michelle L DeOliveira
Journal:  Am J Surg       Date:  2015-06-29       Impact factor: 2.565

9.  Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment.

Authors:  Satoshi Kondo; Tadahiro Takada; Masaru Miyazaki; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Junji Furuse; Hiroya Saito; Toshio Tsuyuguchi; Masakazu Yamamoto; Masato Kayahara; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Satoshi Hirano; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16

10.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.

Authors:  Shahid A Khan; Brian R Davidson; Robert D Goldin; Nigel Heaton; John Karani; Stephen P Pereira; William M C Rosenberg; Paul Tait; Simon D Taylor-Robinson; Andrew V Thillainayagam; Howard C Thomas; Harpreet Wasan
Journal:  Gut       Date:  2012-08-15       Impact factor: 23.059

View more
  5 in total

1.  The quest for optimal and reliable guidelines based on robust evidence for the treatment of cholangiocarcinoma.

Authors:  Daniel Azoulay; David Bomze; Tomer Meirson
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

2.  18F-fluorodeoxyglucose positron emission tomography for intrahepatic cholangiocarcinoma N- and M-staging: should guidelines recommend it at last?

Authors:  Maurizio Zizzo; Magda Zanelli; Francesca Sanguedolce; Annibale Versari; Pierpaolo Pattacini; Andrea Morini; Federica Mereu; Antonia Lavinia Zuliani; Alessandro Giunta
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

3.  An exploration of how developers use qualitative evidence: content analysis and critical appraisal of guidelines.

Authors:  Yun-Yun Wang; Dan-Dan Liang; Cui Lu; Yue-Xian Shi; Jing Zhang; Yue Cao; Cheng Fang; Di Huang; Ying-Hui Jin
Journal:  BMC Med Res Methodol       Date:  2020-06-17       Impact factor: 4.615

4.  Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.

Authors:  Peng Liao; Li Cao; Hang Chen; Shui-Zi Pang
Journal:  Medicine (Baltimore)       Date:  2021-04-23       Impact factor: 1.817

5.  Evidence summary of human milk fortifier in preterm infants.

Authors:  Xin Gu; Xiaofen Shi; Limin Zhang; Ying Zhou; Yinghua Cai; Wujia Jiang; Qunyan Zhou
Journal:  Transl Pediatr       Date:  2021-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.